Researchers and medical professionals are increasingly preferring to use 3D bioprinting as a reliable option for more personalized treatment of patients. According to experts, this method has the ability to enhance the quality of life, in addition to reducing costs of health systems. Spain has been a leading nation where this kind of technology is emerging at a greater pace. REGEMAT 3D is the latest company trying to improve clinical results by means of bioprinting. The company sources reveal, it is trying hard to curb methods of cosmetic testing on animals. The method of biotechnology reduces the time required for drugs to go through development phases and also makes it available for patients faster. The drug development process is usually lengthy and costly, it takes nearly ten years for a new medicine to complete the preliminary process from initial discovery to its reach in the marketplace. Sources allege, REGEMAT 3D is making tools available for pharmaceutical researchers who focus on producing new drugs and for those who are continually looking for innovative solutions for patients. With the help of REGEMAT 3D’s V1 printer, Faculty of Pharmacy, University of Seville for instance manufactured pharmaceutical dosage with a 3D printer for the first time. In Norway, Garry Chinga Carrasco, a lead scientist in the biocomposites area at RISE PFI AS, is also allegedly working with REGEMAT 3D’s V1 bioprinter. This helps to create wound dressings for the skin and for other similar applications, like printing tissue models. REGEMAT 3D biotechnology was also used by Francisco Jose Calero Castro, a specialist in biomedical investigation. He is using 3D mesh to simulate prostheses. These are only a couple of examples of application of 3D technology which are moving quickly in Spain.
Tags : REGEMAT 3D technology, 3D bioprinting, REGEMAT 3D, Garry Chinga Carrasco, Biotechnology,